2014-02-15T13:26:07-06:00 2013-06-30 860683059 BEACHFLEISCHMAN PC PO BOX 64130 TUCSON AZ 857284130 990 2012-07-01 201991334 CRITICAL PATH INSTITUTE CRIT 5205473440 1730 EAST RIVER ROAD NO 200 TUCSON AZ 857185898 STEVEN BROADBENT MBA 5205473440 2014-02-07 1 KAREN K MCCLOSKEY CPA P00099644 5203214600 2012 2015-11-30 17:44:51Z MARTHA BRUMFIELD PHD 1730 EAST RIVER ROAD NO 200 TUCSON AZ 857185898 8915362 0 X WWW.C-PATH.ORG X 2004 AZ FOSTER AND CONDUCT RESEARCH AND EDUCATIONAL PROGRAMS THAT WILL LEAD TO SAFER MEDICAL PRODUCTS. 13 12 61 1 0 0 7998909 5915630 2560898 2977903 21292 2525 20745 311 10601844 8896369 463426 778641 0 0 5755668 4200117 0 0 42013 4187345 4370872 10406439 9349630 195405 -453261 9068693 8716861 5103811 5205240 3964882 3511621 X THE CRITICAL PATH INSTITUTE IS A CATALYST IN THE DEVELOPMENT OF NEW APPROACHES THAT ADVANCE MEDICAL INNOVATION AND REGULATORY SCIENCE. THIS IS ACHIEVED BY LEADING TEAMS THAT SHARE DATA, KNOWLEDGE AND EXPERTISE RESULTING IN SOUND, CONSENSUS BASED SCIENCE. 0 0 7517498 778641 2977903 THE CRITICAL PATH INSTITUTE (C-PATH) IS AN INDEPENDENT, NON-PROFIT ORGANIZATION UNIQUELY DEDICATED TO IMPLEMENTING THE FDA'S CRITICAL PATH INITIATIVE BY CREATING COLLABORATIONS AMONG REGULATORS (SCIENTISTS FROM THE FDA) AND THE REGULATED (MEDICAL PRODUCT INDUSTRY) THAT RESULT IN ACCELERATED DEVELOPMENT OF SAFE, NEW MEDICAL PRODUCTS. THE ACCOMPLISHMENTS FOR THIS FISCAL YEAR ARE SUMMARIZED BELOW.THE COALITION AGAINST MAJOR DISEASES (CAMD) WAS CREATED TO DEVELOP TOOLS AND PROCESSES TO ACCELERATE PROGRESS IN THE PREVENTION, TREATMENT AND CURE OF MAJOR NEURODEGENERATIVE DISEASES, INITIALLY FOCUSING ON ALZHEIMER'S AND PARKINSON'S DISEASES. ACCOMPLISHMENTS INCLUDE: 1) A PUBLIC DATABASE OF ALZHEIMER'S DISEASE CLINICAL TRIALS CONTINUES TO GROW IN SIZE AND USE. DATA FROM TWENTY FOUR CLINICAL TRIALS OF MEMBER COMPANIES COMPRISING 6,500 PATIENTS HAVE BEEN REMAPPED INTO THE NEW DATA STANDARD. THE DATABASE IS BEING USED BY NEARLY 250 SCIENTISTS FROM AROUND THE WORLD. 2) A DISEASE PROGRESSION MODEL CREATED FROM USE OF THE DATA FROM THE DATABASE, AND DATA FROM THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE STUDIES. THE MODEL, ALONG WITH A SIMULATION INFRASTRUCTURE, HAS BEEN FORMALLY ENDORSED BY THE FDA AND EMA FOR USE IN DESIGNING CLINICAL TRIALS FOR ALZHEIMER'S DISEASE. 3) A SERIES OF CEREBRAL SPINAL FLUID (CSF) AND HIPPOCAMPAL IMAGING BIOMARKERS WHICH HAVE BEEN STUDIED FOR USE IN IDENTIFYING EARLY SYMPTOMATIC PATIENTS WITH A HIGH LIKELIHOOD OF PROGRESSION TO DEMENTIA IN A SHORT PERIOD OF TIME. SUCH PATIENTS WOULD BE INCLUDED IN CLINICAL TRIALS OF THERAPIES FOR ALZHEIMER'S DISEASE. LOW HIPPOCAMPAL VOLUME HAS BEEN QUALIFIED BY THE EUROPEAN MEDICINES AGENCY (EMA), AND A RESEARCH PLAN FOR BOTH SETS OF BIOMARKERS HAS BEEN SUBMITTED TO THE FDA. CAMD MEMBERS HAVE MET WITH AND RECEIVED FEEDBACK FROM THE FDA, HAVE RESPONDED TO THEIR QUESTIONS AND ARE NOW EXECUTING THE RESEARCH PLAN. 4) THE CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM (CDISC) STANDARD FOR PARKINSON'S DISEASE HAS BEEN DEVELOPED AND PUBLISHED AND IS AVAILABLE FOR USE. 5) AN UPDATED VERSION OF THE ALZHEIMER'S DISEASE CDISC STANDARD WAS DEVELOPED TO INCLUDE DATA ELEMENTS FOR PRE-DEMENTIA, ADDITIONAL COGNITIVE SCALES, AND ADDITIONAL BIOMARKERS. 6) A BRIEFING PACKAGE FOR SPECT IMAGING OF DOPAMINE TRANSPORT ACTIVITY FOR USE AS A CLINICAL TRIAL ENRICHMENT CRITERION FOR PARKINSON'S DISEASE HAS BEEN SUBMITTED TO THE FDA FOR ADVICE. 7) AN EFFORT HAS BEGUN TO DEVELOP AN IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT FOR EARLY STAGES OF ALZHEIMER'S DISEASE.THE PATIENT-REPORTED OUTCOME CONSORTIUM (PRO) WAS CREATED TO IDENTIFY AND PRIORITIZE THE MEDICAL PRODUCT DEVELOPMENT AREAS WHERE PRO INSTRUMENTS ARE NEEDED, AS WELL AS TO SUBMIT QUALIFICATION DOSSIERS TO REGULATORY AGENCIES FOR QUALIFICATION OF PRO INSTRUMENTS FOR USE IN REGULATORY AND DRUG DEVELOPMENT DECISION MAKING. THE FOLLOWING WORKING GROUPS HAVE SUBMITTED BRIEFING DOSSIERS TO THE FDA THAT INCLUDE THEIR QUALITATIVE RESEARCH AND A DRAFT INSTRUMENT: COGNITION, IRRITABLE BOWEL SYNDROME, ASTHMA, AND DEPRESSION. TWO WORKING GROUPS, NON-SMALL CELL LUNG CANCER AND FUNCTIONAL DYSPEPSIA, HAVE SUBMITTED BRIEFING DOSSIERS TO THE FDA THAT INCLUDE THE RESULTS OF THEIR CONCEPT ELICITATION, THE PROTOCOL, AND THEIR STUDY DOCUMENTS, AS PART OF THE CONSULTATION AND ADVICE STAGE. RHEUMATOID ARTHRITIS IS COMPLETING THEIR GAP ANALYSIS AND LITERATURE REVIEW.THE PREDICTIVE SAFETY TESTING CONSORTIUM (PSTC) COMPILES, GENERATES, AND SUBMITS FOR REGULATORY REVIEW DATA ON NEW SAFETY BIOMARKERS TO BE USED IN DRUG DEVELOPMENT, THUS ADVANCING THE DRUG SAFETY ASSESSMENT PROCESS. THE NEPHROTOXICITY WORKING GROUP HAS SUBMITTED TWO IMPORTANT BRIEFING PACKAGES TO THE FDA AND EMA: ONE ON KIDNEY CLINICAL SAFETY BIOMARKERS WITH THE LEARNING-PHASE DATA FROM THE HEALTHY VOLUNTEER STUDY AND THE OTHER ON KIDNEY RODENT SAFETY BIOMARKERS FOR A FINAL EVALUATION. STUDIES TO MONITOR THE BIOMARKERS' PERFORMANCE IN PATIENTS WHO ARE ALREADY BEING MONITORED DUE TO NECESSARY TREATMENT WITH POTENTIALLY TOXIC THERAPIES ARE IN PROGRESS AND ARE BEING RUN IN CONJUNCTION WITH THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH. THE SKELETAL MUSCLE WORKING GROUP HAS COMPLETED THEIR RESEARCH AND EVALUATION AND IS NEARLY READY TO SUBMIT THEIR RESULTS IN A FINAL BRIEFING PACKAGE. WORK IS ALSO UNDERWAY TO ASSESS THE VALUE OF PRECLINICAL BIOMARKERS TO DETECT DRUG INDUCED INJURY IN THE VASCULAR AND TESTICULAR SYSTEMS, AND DRUG INDUCED CARDIAC HYPERTROPHY.THE CRITICAL PATH TO TB REGIMENS (CPTR) IS A COLLABORATION WITH THE BILL AND MELINDA GATES FOUNDATION AND THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT. THE GOAL OF THIS COLLABORATION IS TO SIGNIFICANTLY SPEED DEVELOPMENT OF INNOVATIVE TREATMENT REGIMENS FOR TUBERCULOSIS. THE BIOMARKER AND CLINICAL ENDPOINT WORKING GROUP MET WITH THE FDA, AND WITH FDA'S SUPPORT AND ENCOURAGEMENT, ARE WORKING TO INCLUDE THE USE OF QUANTITATIVE LIQUID CULTURE RESULTS FOR DETERMINING TREATMENT SUCCESS OR FAILURE IN THE TB THERAPY DEVELOPMENT GUIDANCE. WORK IS UNDERWAY TO DEVELOP A HOLLOW FIBER MODEL FOR USE TO SELECT DRUG REGIMENS, AND INFORM DOSING DECISIONS. A NEW EFFORT WAS LAUNCHED THIS YEAR TO HELP DEVELOP A RAPID DRUG SENSITIVITY TEST TO AID IN INFORMING APPROPRIATE TREATMENT DECISIONS FOR PATIENTS THAT HAVE DRUG RESISTANT FORMS OF TB. A PARTNERSHIP WITH THE POLYCYSTIC KIDNEY DISEASE (PKD) FOUNDATION TO QUALIFY TOTAL KIDNEY VOLUME AS A PROGNOSTIC BIOMARKER FOR PKD HAS MADE SIGNIFICANT PROGRESS. THE CDISC DATA STANDARD IS COMPLETE WHICH HAS ENABLED A DATABASE TO BE CREATED FROM REGISTRY DATA FROM THREE ACADEMIC INSTITUTIONS AND TWO NIH STUDIES. IT CONTAINS LONGITUDINAL DATA ON OVER 3300 PKD PATIENTS. THE DATA HAS BEEN ANALYZED AND A BRIEFING PACKAGE WAS SUBMITTED TO BOTH THE FDA AND EMA. BOTH AGENCIES ASKED FOR SOME ADDITIONAL DATA AND REQUESTED THAT THE FINAL PACKAGE BE SUBMITTED. A NEW CONSORTIUM WAS LAUNCHED IN COLLABORATION WITH THE NATIONAL MULTIPLE SCLEROSIS (MS) SOCIETY TO DEVELOP DATA STANDARDS FOR MS, CREATE A DATABASE OF EXISTING CLINICAL TRIAL DATA, AND BOTH GENERATE DATA FOR AND ACHIEVE FDA AND EMA QUALIFICATION OF A NEW IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT FOR USE IN CLINICAL TRIALS. TEN PHARMACEUTICAL COMPANIES ARE PARTICIPATING. THE DATA STANDARD IS NEARLY COMPLETE. DATA COLLECTION AND CURATION FROM CONTRIBUTORS IS UNDERWAY. A DRAFT DEFINITION OF THE DISABILITIES IN MS FOR THE PURPOSE OF DEVELOPING THE PERFORMANCE MEASUREMENT IS ALSO COMPLETE. A LETTER OF INTENT DESCRIBING THE NEED FOR AND APPROACH TO DEVELOP A NEW CLINICAL OUTCOME ASSESSMENT TOOL WAS SUBMITTED TO BOTH THE EMA AND FDA. REGULATORY FEEDBACK WAS POSITIVE. 7517498 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 34 0 1 61 1 0 0 0 0 0 0 0 0 0 0 X 13 12 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 1 1 1 0 AZ X ALLISON SCHOTT 5206478380 1730 EAST RIVER ROAD SUITE 200 TUCSON AZ 857185898 THORIR BJORNSSON MD 32.00 X 140352 0 12058 J LYLE BOOTMAN PHD SCD 1.00 X 0 0 0 CRAIG BRATER MD 1.00 X 0 0 0 SAM BRODER 1.00 X 0 0 0 JOHN CARTER 1.00 X 0 0 0 M WAINWRIGHT FISHBURN JR 1.00 X 0 0 0 JAMES GREENWOOD 1.00 X 0 0 0 MICHAEL KASSER MBA PHD 1.00 X 0 0 0 SHAUN A KIRKPATRICK MA 1.00 X 0 0 0 JAMES T KOLBE 1.00 X 0 0 0 WALTER H MOOS PHD 1.00 X 0 0 0 RICHARD T MYERS JR 1.00 X 0 0 0 CINDY PARSEGHIAN 1.00 X 0 0 0 LESLIE P TOLBERT PHD 1.00 X 0 0 0 ALASTAIR JJ WOOD MD CHB 1.00 X 0 0 0 PETER B CORR MD PHD 1.00 X X 0 0 0 JEFFREY JACOB SM 1.00 X X 0 0 0 RAYMOND L WOOSLEY MD PHD 60.00 X X 126599 0 18488 CAROLYN COMPTON MD PHD 60.00 X X 367689 0 24002 MARTHA BRUMFIELD PHD 60.00 X X 0 0 0 CELINDA JOHNSON 40.00 X X 98516 0 13494 ENRIQUE AVILES 50.00 X X 139925 0 22180 JOYCE ROGERS CMA MBA 40.00 X 100109 0 8929 RICHARD T MYERS 50.00 X 30927 0 5135 STEVEN BROADBENT MBA 50.00 X 172772 0 24911 ESLIE DENNIS MD 40.00 X 242980 0 30236 LYNN HUDSON PHD 40.00 X 180595 0 16524 STEPHEN COONS PHD 40.00 X 166457 0 20061 DIANE STEPHENSON PHD 40.00 X 149258 0 26299 DEBRA HANNA PHD 40.00 X 148918 0 22007 2065097 0 244324 13 0 1 0 UNITED BIOSOURCE CORPORATION LOCKBOX 758641 BALTIMORE MD 21275 RESEARCH 489535 FOUNDATION FOR THE NATIONAL INSTITUTES O 9650 ROCKVILLE PIKE BETHESDA MD 20814 RESEARCH 315000 ADELPHI VALUES ADELPHI MILL BOLLINGTOR CHESHIRE 105JB UK RESEARCH 308637 PHARSIGHT CORPORATION BOX 200854 PITTSBURGH PA 15251 CONSULTING 280619 HEALTH RESEARCH ASSOCIATES 6505 216TH STREET SW SUITE 105 MOUNTLAKE TERRACE WA 98043 RESEARCH 188320 7 2165121 3750509 500 5915630 RESEARCH SUPPORT FEES 541700 2880721 2880721 OTHER REVENUE 900099 97182 97182 2977903 4957 4957 16322 16011 311 311 311 550 2982 -2432 -2432 -2432 8896369 2977903 0 2836 X 778641 778641 1030137 557467 463394 9276 2525727 1881129 629063 15535 178520 128612 48779 1129 234140 167917 64376 1847 231593 158641 71331 1621 60704 49777 10684 243 101461 70164 30580 717 60071 41149 18501 421 2614071 2508370 103352 2349 57447 39998 17061 388 178733 140880 37012 841 147995 129744 17845 406 477287 277014 195459 4814 275878 240466 34442 970 162283 157302 4644 337 160902 133978 26326 598 33221 22756 10232 233 BAD DEBT 16953 13975 2912 66 DUES AND SUBSCRIPTIONS 11973 9073 2709 191 MISCELLANEOUS 11893 10445 1417 31 9349630 7517498 1790119 42013 753417 1387790 3933771 3572128 49318 371966 689104 730459 70002 59428 906504 730313 328372 176191 3217568 2403428 27141 15471 9068693 8716861 312161 647230 4791650 4558010 5103811 5205240 X 3807584 3457126 157298 54495 3964882 3511621 9068693 8716861 -453261 0 X 0 1 X 1 1 1 X 5016728 5617050 7857830 7998908 5915630 32406146 5016728 5617050 7857830 7998908 5915630 32406146 501585 31904561 34114 30965 34431 22660 21279 143449 17970 41243 30697 20745 110655 32660250 9593746 0.97690 0.97850 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 60071 60071 9289559 9349630 617482 154371 0 0 467663 630748 670322 617482 2386215 3579323 108342 108886 109805 60071 387104 116916 157687 167581 154371 596555 894833 136608 91911 44697 312884 230060 82824 457012 408342 48670 176191 X 8915780 968 968 8914812 -18443 -18443 8896369 9369041 968 18443 19411 9349630 0 9349630 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X, LINE 2: FINANCIAL STATEMENT FIN 48 (ASC 740) FOOTNOTE: C-PATH IS EXEMPT FROM INCOME TAXES UNDER BOTH FEDERAL (INTERNAL REVENUE CODE SECTION 501(C)(3)) AND ARIZONA INCOME TAX LAWS, AND IS CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION. ACCORDINGLY, NO PROVISION FOR FEDERAL AND STATE INCOME TAXES IS MADE IN THE FINANCIAL STATEMENTS. INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO C-PATH'S TAX-EXEMPT PURPOSE, HOWEVER, MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS TAXABLE INCOME (UBTI). GAAP REQUIRES MANAGEMENT TO PERFORM AN EVALUATION OF ALL TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN THE COURSE OF PREPARING C-PATH'S TAX RETURNS TO DETERMINE WHETHER THE TAX POSITIONS MEET A "MORE LIKELY THAN NOT" STANDARD OF BEING SUSTAINED UNDER EXAMINATION BY THE APPLICABLE TAXING AUTHORITIES. THIS EVALUATION IS REQUIRED TO BE PERFORMED FOR ALL OPEN TAX YEARS, AS DEFINED BY THE VARIOUS STATUTES OF LIMITATIONS, FOR FEDERAL AND STATE PURPOSES. C-PATH IS ONLY SUBJECT TO INCOME TAXES ON UBTI AS APPLICABLE. AS A RESULT, C-PATH IS REQUIRED TO FILE INFORMATIONAL RETURNS FOR FEDERAL AND STATE PURPOSES AND, IF IT HAS UBTI, FEDERAL AND STATE INCOME TAX RETURNS. WITH LIMITED EXCEPTIONS, C-PATH IS NO LONGER SUBJECT TO TAX EXAMINATION FOR ANY YEARS EARLIER THAN 2010 FOR FEDERAL AND 2009 FOR STATE. MANAGEMENT HAS PERFORMED ITS EVALUATION OF TAX POSITIONS TAKEN ON ALL OPEN TAX RETURNS AND HAS DETERMINED THAT THERE WERE NO POSITIONS TAKEN THAT DO NOT MEET THE "MORE LIKELY THAN NOT" STANDARD. PART XI, LINE 4B - OTHER ADJUSTMENTS: LOSS ON DISPOSAL OF ASSET -2,432. LOSS ON SUBLEASE -16,011. PART XII, LINE 2D - OTHER ADJUSTMENTS: LOSS ON DISPOSAL OF ASSET 2,432. LOSS ON SUBLEASE 16,011. 1 INSTITUTE ON SCIENCE FOR GLOBAL POLICY 3320 N CAMPBELL AVE SUITE 200 TUCSON AZ 85719 453998749 501(C)(3) 735701 CPATH ACTED AS FISCAL SPONSOR WHILE ISGP OBTAINED TAX EXEMPT STATUS UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 STATE OF TEXAS 42940 RESEARCH FOR CPTR CONSORTIUM 2 0 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. X X 0 1 X X X X X X 1 0 0 0 0 0 0 0 0 THORIR BJORNSSON MD 140352 0 0 0 0 0 11194 0 864 0 152410 0 0 0 CAROLYN COMPTON MD PHD 142689 0 0 0 225000 0 22258 0 1744 0 391691 0 0 0 ENRIQUE AVILES 139925 0 0 0 0 0 11405 0 10775 0 162105 0 0 0 STEVEN BROADBENT MBA 172772 0 0 0 0 0 14014 0 10897 0 197683 0 0 0 ESLIE DENNIS MD 242980 0 0 0 0 0 19600 0 10636 0 273216 0 0 0 LYNN HUDSON PHD 180595 0 0 0 0 0 14400 0 2124 0 197119 0 0 0 STEPHEN COONS PHD 166457 0 0 0 0 0 13388 0 6673 0 186518 0 0 0 DIANE STEPHENSON PHD 149258 0 0 0 0 0 12000 0 14299 0 175557 0 0 0 DEBRA HANNA PHD 148918 0 0 0 0 0 12000 0 10007 0 170925 0 0 0 PART I, LINE 1B HEALTH CLUB DUES WERE PROVIDED TO THE PRESIDENT/CEO. THERE WAS NOT A SPECIFIC WRITTEN POLICY FOR THIS, BUT WAS IN ACCORDANCE WITH INSTRUCTIONS FROM THE BOARD OF DIRECTORS. PART I, LINE 4A CAROLYN COMPTON RECEIVED A PAYMENT OF $225,000 UNDER THE TERMS OF HER SEVERANCE AGREEMENT. FORM 990, PART VI, SECTION A, LINE 8B THERE ARE NO COMMITTEES WITH AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11 FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE ORGANIZATION'S ACCOUNTING ASSOCIATE, COO, PRESIDENT/CEO, AND ANOTHER OUTSIDE CPA PRIOR TO BEING FINALIZED. FORM 990, PART VI, SECTION B, LINE 12C OFFICERS AND DIRECTORS MUST FILL OUT CONFLICT OF INTEREST DISCLOSURES ANNUALLY. EMPLOYEES COMPLETE THE CONFLICT OF INTEREST FORM UPON HIRING AND UPDATE THE DOCUMENT AS NEEDED. EMPLOYEES ARE REMINDED ANNUALLY TO REVIEW THEIR STATUS. THESE DISCLOSURES ARE REVIEWED BY THE PRESIDENT/CEO AND THE COO. FORM 990, PART VI, SECTION B, LINE 15 A BOARD OF DIRECTORS COMPENSATION COMMITTEE MEETS AND REVIEWS EXECUTIVE COMPENSATION ANNUALLY. EVERY FEW YEARS THE COMMITTEE SEEKS AN INDEPENDENT COMPENSATION CONSULTING ORGANIZATION. AFTER THE CONSULTING ORGANIZATION HAS BEEN RETAINED, THE COMPENSATION COMMITTEE RECEIVES THE CONSULTANT'S EXECUTIVE COMPENSATION REVIEWS AND RECOMMENDATIONS. THIS INFORMATION IS THEN USED AS A BASIS FOR THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF DIRECTORS. AN OVERALL SALARY PROGRAM FOR EMPLOYEES MUST BE APPROVED BY THE BOARD OF DIRECTORS BEFORE IMPLEMENTATION. ALL EMPLOYEE SALARY INCREASES MUST BE APPROVED BY THE PRESIDENT/ CEO. THE LAST INDEPENDENT COMPENSATION SURVEY WAS CONDUCTED FOR THE CEO IN AUGUST 2011. FORM 990, PART VI, SECTION C, LINE 19 ARTICLES OF INCORPORATION CAN BE FOUND ON THE ARIZONA CORPORATION COMMISSION WEBSITE. THE CONFLICT OF INTEREST POLICY AND THE FINANCIAL STATEMENTS (VIA THE ANNUAL REPORT) ARE POSTED ON THE INSTITUTE'S WEBSITE. OTHER FEES FORM 990, PART IX, LINE 11G RESEARCH SUPPORT SERVICES: PROGRAM SERVICE EXPENSES 1,980,305. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,980,305. CONSULTING: PROGRAM SERVICE EXPENSES 339,727. MANAGEMENT AND GENERAL EXPENSES 19,798. FUNDRAISING EXPENSES 450. TOTAL EXPENSES 359,975. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 188,338. MANAGEMENT AND GENERAL EXPENSES 83,554. FUNDRAISING EXPENSES 1,899. TOTAL EXPENSES 273,791. THE CRITICAL PATH FOUNDATION 1730 EAST RIVER ROAD SUITE 200 TUCSON AZ 85718 204780896 RAISING AND CONTRIBUTING FUNDS TO CRITICAL PATH INSTITUTE AZ 501(C)(3) 11 CRITICAL PATH INSTITUTE 1 CRITICAL PATH GLOBAL LTD 1730 EAST RIVER ROAD SUITE 200 TUCSON AZ 85718 FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY UK CRITICAL PATH INSTITUTE 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0